Abstract
Background: Overactive bladder (OAB) is a common and distressing condition that impairs quality of life. Mirabegron, a β₃-adrenoceptor agonist, offers an effective and better-tolerated alternative to traditional antimuscarinic agents.
Objective: To evaluate the clinical efficacy and safety of Mirabegron in patients presenting with OAB.
Methods: A total of 85 patients clinically diagnosed with OAB were enrolled and treated with Mirabegron 50 mg once daily. Treatment response, comorbidities, and adverse events were assessed using a structured proforma and analyzed statistically.
Results: Clinical improvement was observed in 66 patients (77.6%), whereas 19 patients (22.4%) showed no significant response. The mean age of participants was 48.5 ± 9.1 years, with 67.1% females and 32.9% males. The mean BMI was 27.3 ± 3.5 kg/m², and median symptom duration was 8 months (IQR 5–14). Diabetes mellitus (p = 0.041) and hypertension (p = 0.038) were significantly associated with reduced treatment response. Only 3.5% of patients reported mild, non-serious adverse effects, with no discontinuations.
Conclusion: Mirabegron 50 mg daily demonstrates high efficacy (77.6%) and excellent tolerability in managing OAB. The presence of diabetes and hypertension may attenuate therapeutic response, emphasizing the importance of individualized treatment strategies.